Conference Coverage: EHA 2024 – Focus on Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)
Expert perspectives on the latest therapeutic developments, treatment approaches, and implications for clinical decision-making regarding leukemia
Faculty Chair
Elias Jabbour, MD
MD Anderson Cancer Center, Houston, TX, USA
Faculty Members
Daniel Pollyea, MD, MS
University of Colorado School of Medicine, Aurora, CO, USA
Courtney DiNardo, MD
MD Anderson Cancer Center, Houston, TX, USA
Uma Borate, MD, MBBS
The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
Tapan Kadia, MD
MD Anderson Cancer Center, Houston, TX, USA
Rami Komrokji, MD
Moffitt Cancer Center, Tampa, FL, USA
Eytan Stein, MD
Memorial Sloan Kettering Cancer Center, New York, NY, USA
Alexander E. Perl, MD
Abramson Cancer Center, Penn Medicine, Philadelphia, PA, USA
KEY TAKEAWAYS AND STRATEGIC INSIGHTS
- Advances in AML: Newly Diagnosed
- Advances in AML: R/R Disease – Monotherapies
- Advances in AML: R/R Disease – Combination Therapies
- New Developments in First-Line Treatment of MDS
- New Developments in Treatment of R/R MDS
